0001193125-26-222843
SEC filingPyxis Oncology reported widening operating and net losses in Q1 FY2026, reflecting continued clinical-stage investment and non-cash expense dynamics, as the company maintains its trajectory of significant operating losses since inception.
Diluted EPS was $-0.37 for Q1 FY2026, compared to $-0.35 in the prior-year period — a 5.7% decline. The change reflects both the increase in net loss and an expanded weighted-average diluted share count, underscoring the dilutive impact of equity-based compensation and financing activity common among clinical-stage biopharmaceutical companies.
Net cash used in operating activities was -$26.0 million in Q1 FY2026, compared to -$22.5 million in Q1 FY2025. This increase in cash outflow aligns with management’s stated expectation that research and development expenses will increase substantially in connection with ongoing and planned preclinical and clinical development activities. The change also reflects lower interest and investment income, partially offset by higher sublease income — a dynamic noted in Item 2 of the Management Discussion.
The company reiterates that expenses and capital expenditures will increase substantially in connection with ongoing activities. This includes expected growth in research and development spending tied to clinical trials and preclinical work. There is no indication of near-term profitability; instead, the narrative emphasizes sustained investment as necessary to advance the pipeline. These expectations are not speculative but grounded in disclosed operational realities: clinical-stage status, recurring non-cash compensation, and structural cash burn inherent to late-phase oncology development.